Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2010

Pfizer to Assess Tekmira Technology to Deliver siRNAs in Preclinical Models

  • Tekmira and Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver siRNA molecules provided by Pfizer. Tekmira will be responsible for preparing the SNALP formulations, and Pfizer will evaluate the formulations in preclinical models.

    SNALP technology encapsulates siRNAs in uniform lipid nanoparticles, which are effective in delivering RNAi therapeutics to disease sites in preclinical models, according to Tekmira. SNALP formulations are manufactured by a proprietary method that is robust, scalable, and highly reproducible, the firm adds.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »